Introduction
Ras proteins (Ki-, Ha-, and N-Ras) are three closely related members of the Ras family, which controls various cellular processes, such as growth and proliferation [1] .
Oncogenic mutants of ras genes are found in about 30 % of human tumors. Especially, pancreatic adenocarcinoma is the tumor with the highest incidence of Ki-ras point mutations, occuring in 70 to 90% of all cases [2] .
Ras cycles between a GTP-bound form (Ras-GTP) and a GDP-bound form (Ras-GDP).
The active Ras-GTP is converted to the inactive Ras-GDP by intrinsic GTPase activity, which is accelerated by the GTPase-activating protein (Ras-GAP) [1] . Oncogenic Ras is associated with Ras-GAP [3] , where it is insensitive to catalysis by GAP [4] . Therefore, oncogenic Ras always remains in the GTP-bound form, which cannot switch off the downstream signal.
Several types of GAP proteins for Ras have been identified in mammalian cells, including p120-GAP, neurofibromin (the product of Nf1 tumor-suppressor gene) and GAP1 [5] . The classical Ras-GAP, p120-GAP, has two Src-homology (SH)2 and one SH3 domains. SH domains of p120-GAP function as effectors by associating with several tyrosine-phosphorylated proteins [5] , which induce Ras-dependent gene expression [6] and repress adhesion [7] . In addition, p120-GAP is involved in Ras transformation [8, 9] , cell survival [10, 11, 12] tumor cell invasion [13] , and v-Src-induced cytoskeletal disruption [14] . Based on these findings, p120-GAP proteins show promise as a target for anticancer approaches [11] . However, it is still not clear that p120-GAP contributes to the tumor cell activity, since full Ras function requires multiple downstream pathways, i.e.
cascades from Raf to extracellular signal-regulated kinase (ERK), from p120-GAP to p190
Rho-GAP, and from phosphatidylinositol 3-kinase (PI3K) to AKT [1] .
The 100 kDa Ras-GAP1 family contains two closely related proteins, GAP1 m [15] 3 and GAP1 IP4BP [16] / GAPIII (a mouse homologue of GAP1 IP4BP ) [17] . Though roles of GAP1 are not completely clear, its distinct perinuclear localization [18] leads us to expect that GAP1 m might be involved in the transcriptional process. Physiologically, GAP1 has the G protein (Gα12)- [19] and inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P 4 )-binding sites [20] , and activates inositol tetrakisphosphate (IP 4 )-gated Ca 2+ influx [21] . The same line of evidence is provided by us that bradykinin and Ins(1,3,4,5)P 4 induce continuous Ca 2+ influx in oncogenic ras-transformed NIH/3T3 fibroblast DT cells [22] , predicting the up-regulated GAP1 function [23, 24] .
To know whether Ras-Gap gene expressions are up-regulated and linked to the tumor biological activity in ras-tranformed cells, we compared mRNA expressions of four ras-Gap genes (p120-Gap, Gap1 m , GapIII, Nf1) between DT [25] and parental NIH/3T3 cells, and studied their sensitivity to anti-cancer drugs. We also measured the viral oncogene v-Ki-ras, PIK3CA which encodes the p110α catalytic subunit of PI3K [1] , p53 that encodes a transcription factor which induces cellular senescence in response to oncogenic Ras signals [26] , and PTEN tumor suppressor gene that encodes a phosphatase [27] which inhibits ras transformation in NIH/3T3 cells [28] .
Materials and methods
Cell culture. v-Ki-ras-transformed NIH/3T3 fibroblasts (DT) [25] cycles using β-actin primers. Reverse transcription reactions were performed by 5 μg of total RNA in 20 μl of DNase-, RNase-free water with murine reverse transcriptase and random hexadeoxynucleotides, using a first-strand cDNA synthesis kit.
Real-time quantitative reverse transcription-PCR (QRT-PCR).
Primers were designed to amplify segments of <150 bp to maximize efficiency, which are summarized in Table 1 . Expressions of the above genes were determined by QRT-PCR using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA).
PCR reaction was performed with SYBR Green, the double-strand DNA-selective fluorescent dye. 25-μl of reaction mixture was composed of 12.5 μl of 2X SYBR Green PCR Master Mix, 500 nmol/l forward primer, 500 nmol/l reverse primer and 1.1 ng of first-strand cDNA. Data were analyzed using GeneAmp 7700 sequence detection system The PCR products were also examined using 2% agarose gel electrophoresis. After ethidium bromide staining, bands were visible only at the expected molecular weights for each target mRNA product.
Western blot. Cells were treated with SDS buffer including 0.2% β-mercaptoethanol.
15 μg of the samples for each lane was analyzed on a 10% SDS-PAGE followed by blotting on a nitrocellulose membrane. The membrane was incubated with antibodies, and subsequently visualized using the chemiluminescent solution. The visualized signals was analyzed by J-image software.
Cell count. Viable cell numbers were determined by trypan blue dye exclusion counted in a Neubauer-type hemocytometer. All experiments were performed in duplicate and repeated 3 times. Goat anti-mouse IgG antibodies and chemiluminescent solution were obtained from Pierce (Rockford, IL, USA). Molecular weight size marker was purchased from Invitrogen.
Sources of Drugs. EGF, doxorubicin and monoclonal anti-β-actin antibodies

Results and Discussion
p120-Gap, Gap1 m and PIK3CA overexpression in DT cells
In this study we investigated the biological activity of oncogenic v-Ki-ras transformed clone (DT cells) by measuring mRNA levels of ras-related genes. Fig. 1A shows comparative mRNA expression analysis of DT cells versus parental NIH/3T3 cells.
p120-Gap and Gap1 m mRNA expressions were higher in DT cells by 9.3-fold and 12.2-fold over the parental cells, respectively (mean value). PIK3CA expression was also higher by 6.2-fold. mRNA expressions of other target genes, GapIII, Nf-1, PTEN and p53, were at the similar levels between DT and NIH/3T3 cells. p120-GAP protein expressions were also increased in DT cells by 2.6-fold (Fig. 1B) .
We also tested mRNA levels of ras-Gap genes in the different cells. In another Our results are in accord with the role of PIK3CA implicated as an oncogene in ovarian cancer [30] . Besides our results are novel in that p120-Gap and Gap1 m genes are involved in ras-transformation. Therefore, it could be predicted that the up-regulated ras-Gap genes as well as PIK3CA facilitate DT cell survival.
Next, we studied effects of growth factors on gene expressions. 2 hrs after stimulation of DT cells with 10 % FCS or EGF (25 ng/ml), p120-Gap expression was increased by 8.0-and 5.0-fold of the serum-starved level, respectively ( Fig. 2A-a and -c) .
PIK3CA expression was also strongly induced after stimulation with growth factors.
Gap1 m expression was slightly induced after stimulation with FCS and EGF by 3.3-fold and 2.9-fold, respectively. On the other hand, apparent changes of GapIII and Nf-1 expressions were not detected either by FCS or EGF in this study ( Fig. 2A-a) . As shown in Fig Fig. 2B-a) .
PD98059 selectively reduces p120-Gap and Gap1 m mRNA expressions in DT cells
To determine whether these overexpressed genes are positively or negatively involved in DT cell survival, effects of several anti-cancer drugs on gene transcription were studied.
Treatment of DT cells with the specific MEK inhibitor PD98059 (50 μM) for 48 hrs selectively decreased the expression levels of p120-Gap and Gap1 m mRNA to -9.6-fold and -12.3-fold, respectively ( Fig. 3A-a) . 6 other genes stayed at almost the same level.
PD98059 did not affect the steady-state mRNA levels of all target genes in NIH/3T3 cells ( Fig. 3A-b) . We also performed a time course analysis of mRNA levels of p120-Gap and Gap1 m genes in PD-treated DT cells. PD98059 caused rapid decreases during the initial 4 hrs in the expression of both p120-Gap and Gap1 m , followed by gradual decreases during the next 5 -24 hrs (data not shown). The result suggests that expressions of p120-Gap and Gap1 m are regulated by factor(s) downstream of MEK. A plausible one is the activator protein-1 (AP-1) transcription factor, such as cJun and Fra1 [31] .
Blocking overexpression of ras-Gap genes by doxorubucin in DT cells
To determine whether common chemotherapeutic agents affect target gene transcription in DT cells, we focused on the topoisomerase II (topo II) poison, doxorubicin (adriamycin). Doxorubicin (10 μM) treatment for 4 hrs caused selective reduction in
Gap1 m expression to -5.1-fold among 8 genes tested in DT cells ( Fig. 3B-a) .
Suppression of Gap1 m expression after 4 hrs of treatment was prior to apparent growth arrest or apoptosis (Fig. 4B) . Doxorubicin did not affect the steady-state mRNA levels of all target genes in NIH/3T3 cells ( Fig. 3B-b ). Time course analysis shows that p120-Gap expression level was also reduced to -6.5-fold after 12 hrs of doxorubicin treatment ( Fig.   4A-a) . After 24 hrs of treatment, p120-Gap and Gap1 m expressions were equally reduced (-9.9 and -9.6-fold). In contrast to this, Expressions of 6 other genes were less modulated until after 12 hrs of treatment (Fig. 4A) . Thus, doxorubicin treatment down-regulated overexpression of p120-Gap and Gap1 m genes in DT cells. These results implicate that the reduced ras-Gap mRNA levels contribute to the growth inhibitory properties of doxorubicin. For a mechanism of down-regulation of ras-Gap genes, the topo II poison doxorubicin might suppress the expression of immediate early genes. A plausible target is the AP-1, since AP-1 activity reflects the tumor sensitivity to doxorubicin [32] .
Effect of trichostatin A on ras-Gap and p53 mRNA expressions in DT cells
Histone deacetylase (HDAC) inhibitors induce morphological reversion in various tumors [33] , thus hold promise as anticancer agents. We studied whether trichostatin A (TSA), a specific HDAC inhibitor, regulates the transcription of ras-related genes in DT cells. TSA (100 ng/ml) treatment for 12 hrs reduced p120-Gap, Gap1 m and p53
expressions of DT cells to -5.3, -4.6, and -12-fold of the pre-treated level, respectively ( Fig. 3B-a) . It did not affect the steady-state mRNA levels of all target genes in NIH/3T3 cells, with the exception of p53 (-13-fold) (Fig. 3B-b) . We found a rapid suppression with a partial recovery of p120-Gap expression, -9.3-fold for 4 hrs and -5.0-fold for 24
hrs of treatment (data not shown).
Effects of PD98059, doxorubicin and TSA on morphology and growth in DT cells.
Finally, in order to understand the biological effects of ras-Gap mRNA overexpression, we studied the modulation of cell morphology and growth by above agents (Fig. 3D ).
After 24 hrs of treatment with PD98059 (50 μM), DT cells of round, thick and non-adherent shapes were altered to be long, flat and adherent shapes, more similar to those of NIH/3T3 cells. After 24 hrs of treatment with doxorubicin (10 μM), survived cells were converted to a flat and adherent shape. TSA (100 ng/ml) treatment for 24 hrs also induced adherent shape in DT cells, as reported previously [33] . The number of DT cells treated with PD, doxorubicin, TSA for 24 hrs was reduced to 39 ± 13 %, 12 ± 3 %, 23
± 12 % of untreated DT cells (n=6), respectively. Thus, treatment with these drugs caused growth arrest and morphological reversion of DT cells to adherent and flat shapes.
As p120 Ras-GAP suppresses focal adhesion by its association with p190 Rho-GAP [7] , our results suggest that the up-regulated p120-Gap causes repression of Rho signaling, leading to the decreased focal adhesion, thereby increases motility in DT cells.
We focused on two sets of information by profiling of mRNA expression in this study.
One is the causal information for tumorigenesis, as discussed above. Another is to find biomarkers for the new molecular specific therapy. Our results indicate that p120-Gap tet-off) and parental (tet-H-ras/CREF: tet-on) cells originally in 10 % FCS condition were serum-starved for 2 hrs, followed by addition of EGF (25 ng/ml) for 2 hrs. 
